TB-500 Side Effects: The Honest Picture for Users

TB-500 usually gets filed under the same safety umbrella as BPC-157 because the two are sold as a matched pair and run on the same timeline. That is a mistake. BPC-157 has small human trials behind it. TB-500, the short synthetic fragment of thymosin beta-4 sold under that name, does not. No completed human trial has ever tested it, at any dose, for any purpose.

This guide is the honest picture, not the community shorthand. What users actually report, why the human evidence is thinner than people assume, the cancer question and why it rests on different ground than BPC-157's version of the same question, and the July 2026 vote on whether TB-500 belongs in a compounding pharmacy, where the advisory committee and the FDA's own reviewers came down on opposite sides. No marketing language, no borrowing BPC-157's safety record for a different molecule.

The Short Answer

At standard doses, reported side effects are mild and limited to the injection site, a brief headache, or short lived lethargy after the shot. Nothing in that list is unusual for a subcutaneous peptide. The honest caveat is bigger than the side effect list: nobody has run the trial that would let anyone say this confidently, and in 2026 the FDA's own reviewers looked at that gap and recommended against allowing TB-500 in pharmacy compounding, even though the advisory committee then voted for it.

The Fragment Problem, and Why It Matters Here

Thymosin beta-4 is a 43 amino acid protein expressed across most human cell types. TB-500 is not that protein. It is a shorter synthetic fragment built around the actin binding region, sold because it is cheaper to manufacture and more stable than the full length peptide. The two share a mechanism story but are not the same molecule by mass, and nothing guarantees they behave the same way once injected.

Every piece of human safety data in this space, the Phase 1 intravenous study in 40 healthy volunteers tolerating doses up to 1260mg, RegeneRx's Phase II wound healing work, Gabriel Sosne's dry eye trials, was run on the full length protein or an ophthalmic formulation of it. None of it was run on the TB-500 fragment. The FDA's review staff reached the same conclusion from the regulatory side in 2026: they found no medical literature of TB-500 itself being administered to patients for any condition, by any route.

This is a sharper version of the gap the TB-500 dosage guide describes for dosing: the numbers in circulation were never validated in a trial. Here the same absence applies to safety, not just to how much to take.

Reported Side Effects By Frequency

Based on community reports across forums, peptide subreddits, and our reader inbox, the side effects that show up with any regularity break down roughly as follows:

• Injection site reactions, mild redness, soreness or a brief sting. The most commonly mentioned effect, and TB-500's larger injection volume (milligram doses rather than BPC-157's micrograms) makes a sore spot slightly more likely, not less.
• Mild headache, usually within a few hours of the shot and resolving on its own. Reported with similar frequency to BPC-157's headache rate.
• Temporary lethargy or a brief "head rush" shortly after injection, more specific to TB-500 than to BPC-157 in community reports, though not well characterized in any formal source.
• Flu-like heaviness in the first day or two of a loading phase, mentioned less often, usually attributed to the higher milligram load during loading rather than to anything specific about the compound.

These are rough estimates from community sampling, not formal pharmacovigilance data, and that caveat matters more here than on most compound pages: there is no clinical trial dataset to check the community numbers against.

The FDA's 2026 Compounding Vote

In April 2026 TB-500 was one of twelve peptides taken off Category 2, the FDA's holding list for bulk substances with safety concerns where it had sat since September 2023, and sent to the Pharmacy Compounding Advisory Committee. The question was whether TB-500, in free base and acetate forms under a wound healing nomination, belongs on the Section 503A list, the list of substances a compounding pharmacy may legally prepare.

The FDA's own review staff recommended against it. Their briefing gave two specific reasons. First, the nomination included no clinical data, and the FDA's own literature review found no record of TB-500 being administered to patients for wound healing or any other condition, by any route. Second, the staff flagged a real concern about immunogenicity, an immune reaction to the peptide itself, for a compound given by subcutaneous or intramuscular injection with aggregation and peptide-related impurities cited as factors that could make that risk worse.

On 23 July 2026 the committee voted 8 to 6, with one abstention, to recommend adding TB-500 anyway. The vote is advisory: nothing changes until the FDA writes it into a rule, and it changes nothing about research-grade vials sold online. Our write-up of the July vote covers all seven peptides on the agenda.

The Cancer and Angiogenesis Question

BPC-157's cancer question is mechanistic: it promotes angiogenesis, and angiogenesis is also how tumors grow, so the concern is theoretical with no supporting data either way in animal models. TB-500's version of this question starts from a different, slightly more concerning place.

Thymosin beta-4 is overexpressed in several human cancers, including pancreatic and colorectal cancer, and that overexpression is studied in the oncology literature as a contributor to tumor angiogenesis and metastatic spread. That is expression data from actual cancer research, not a mechanism inferred from a healing study. It still is not evidence that injecting TB-500 causes cancer or accelerates an existing one, and no case report makes that claim. But it is a different, somewhat firmer category of concern than BPC-157 carries, and treating the two compounds as equally theoretical on this point understates TB-500's side of it.

Immunogenicity: The FDA's Specific Concern

Immunogenicity is the risk that the immune system recognizes an injected peptide as foreign and mounts a response to it, ranging from a local reaction to, in rare cases with other peptide drugs, antibodies that reduce effectiveness over repeated use. FDA review staff flagged this specifically for TB-500 in 2026, citing the potential for aggregation and peptide-related impurities in a subcutaneously or intramuscularly injected product.

This is a real, product-dependent risk rather than a property of the TB-500 sequence itself. Aggregation and impurity load both trace back to manufacturing quality, which is exactly where unregulated research peptide vendors vary the most. A clean, well-characterized peptide carries a lower version of this risk than a poorly made one; the FDA's concern is precisely that nobody is checking.

Drug Interactions

TB-500 has no documented interactions with common medications, largely because there is so little formal study of the fragment to document anything against. The interactions worth noting follow the same logic as other injectable peptides rather than anything specific found for TB-500:

• Blood thinners (warfarin, apixaban): No known interaction, but TB-500's proposed effects on vascular tissue and angiogenesis suggest monitoring is sensible for anyone on chronic anticoagulation.
• Corticosteroids: No known interaction. Both are sometimes used together in tendon and soft tissue recovery protocols, though no formal data covers the combination.
• NSAIDs: No known interaction. Unlike BPC-157, TB-500 has no specific gastric-protective data, so this pairing carries no particular benefit or risk beyond each compound's own profile.
• Other peptides in a stack: The common BPC-157 and TB-500 pairing (see the TB-500 versus BPC-157 comparison and the Wolverine stack page) has no documented interaction between the two, but "no documented interaction" means nobody has looked, not that it has been cleared.

Long-Term Safety: What We Actually Know

Honest answer: less than for almost any other compound on this site. There is no long-term human study of the TB-500 fragment at any dose. The full-length protein has short trials, weeks rather than years, for wound healing and dry eye. The FDA's reviewers went through the available evidence base in 2026 and found nothing further to add.

What exists instead is community use going back roughly as long as BPC-157's, without a documented pattern of serious harm surfacing in that time. That is worth something. It is not a substitute for a trial, and it is a thinner reassurance than BPC-157 can offer, because BPC-157 at least has some human trial data sitting underneath the community record. TB-500 has none.

The honest summary: TB-500's community safety record looks fine so far, the mechanism argument for why it should be well tolerated is reasonable, and none of that changes the fact that the actual evidence base is closer to zero than to thin. Anyone using it for an extended period is, more than with most research peptides, generating the only safety data that exists.

How to Minimize Side Effects

The practical steps that reduce the side effects most users do report:

• Start at the lower end of the loading range. See the TB-500 dosage guide for the numbers; there is no case for starting at the top of a range built on reported practice rather than a trial.
• Rotate injection sites. TB-500's larger per-dose volume makes site rotation more useful here than with BPC-157's smaller doses.
• Hydrate and eat before injecting. Addresses most of the reported headache and lethargy complaints.
• Reconstitute so a full dose fits one syringe barrel. See the arithmetic section of the dosage guide; a dose that requires two draws is two chances to misread the amount, not a safety issue in the injection itself but a real source of dosing error.
• Use third-party tested product. Given the FDA's specific immunogenicity concern around impurities and aggregation, sourcing matters more for TB-500 than for most peptides on this site. Verify a Certificate of Analysis before trusting any vial.

When to Stop Using TB-500

Stop the peptide and seek medical advice if any of the following show up:

• Spreading redness, hives, or swelling at the injection site that extends beyond the local area, which is a more specific concern here given the FDA's immunogenicity flag
• Severe or persistent headache, vision changes, or any neurological symptom
• Chest pain, shortness of breath, or palpitations
• Any new symptom that started with the peptide and does not resolve within 48 hours of stopping

Who Should Not Use TB-500

The short list, based on the two firmest concerns above rather than on documented harm:

• Active cancer, recent cancer history, or strong family history of pancreatic or colorectal cancer specifically, given the expression data behind the angiogenesis concern
• Anyone with a history of significant allergic or immune reactions to injected peptides, given the FDA's specific immunogenicity flag
• Pregnancy or breastfeeding (no data, so the default is avoid)
• Tested athletes under WADA-style rules (thymosin beta-4 and its fragments fall under the same S2 peptide category as BPC-157)

Quality Matters More Than Usual Here

The FDA review staff's stated concern about TB-500 is aggravated by manufacturing quality: aggregation and peptide-related impurities raising immunogenicity risk. That makes vendor sourcing a bigger factor for this specific compound than for peptides with a cleaner regulatory history. A batch Certificate of Analysis from a real lab is the only evidence a buyer has that a given vial is not contributing to the exact risk the agency flagged.

The vendors that consistently provide clean, traceable TB-500 with verifiable Certificates of Analysis are Apollo Peptide Sciences, Pantheon Peptides, Amino Club, and Ascension Peptides. We have checked batches from each against their published COAs.

Frequently Asked Questions

Does TB-500 have the same safety record as BPC-157?

No, and the gap is wider than most comparisons admit. BPC-157 has small human trials behind it. TB-500, the short fragment sold under that name, has no completed human trial of its own. The only human data in the thymosin beta-4 family comes from the full length protein in different formulations, which is not the same molecule by mass or necessarily by effect.

Does TB-500 cause cancer?

No case report documents TB-500 causing cancer. The concern is theoretical: thymosin beta-4 is overexpressed in several human cancers including pancreatic and colorectal, and is implicated in tumor angiogenesis and metastasis in that research literature. That is a signal worth knowing, not proof of harm from using the fragment.

Did the FDA approve TB-500 for compounding?

Not yet. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding TB-500 to the 503A bulk drug substances list, against the advice of the FDA's own review staff, who cited no clinical data, no medical literature of TB-500 given to patients for any condition, and an immunogenicity concern. The vote is advisory and only takes effect if the FDA writes it into a rule.

What are the most commonly reported TB-500 side effects?

Injection site irritation, mild headache, and a brief lethargic or light headed feeling shortly after the shot. These are usually described as mild and self resolving within a day.

Is TB-500 safe long term?

Unknown rather than no. There is no long term human safety study of the fragment at any dose, and the FDA's own reviewers found no clinical literature to draw on in 2026 either. Years of community use without a documented pattern of serious harm is reassuring but is not a substitute for a safety study.

The Bottom Line

TB-500's reported side effect profile, going by community reports, looks mild: injection site soreness, an occasional headache, brief lethargy after the shot. The problem is not the side effect list. It is that almost nothing underneath that list has been tested in a human trial, a gap the FDA's own reviewers confirmed in 2026 when they found no clinical literature on the fragment at all, and that TB-500's cancer question rests on actual tumor expression data rather than pure mechanism, which puts it on slightly firmer and more concerning ground than BPC-157's version of the same worry.

None of this makes TB-500 dangerous. It makes the honest label "under-studied" rather than "safe," and anyone running it should treat sourcing and dose discipline as carrying more of the risk-reduction weight than they would with a better-documented compound. For the full picture including mechanism and the evidence base, see our complete TB-500 guide; for how it compares to its usual stack partner, see TB-500 versus BPC-157.